Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × eribulin × Clear all

Phase

Phase 2 6 Phase 1/2 4 Phase 1 2 Phase 3 1

Status

Completed 9 Active not recruiting 9 Recruiting 7 Not yet recruiting 2 Unknown 1 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cisplatin 46 Carboplatin 44 Radiotherapy 39 Paclitaxel 39 Docetaxel 36 Gemcitabine 32 Cyclophosphamide 32 Rituximab 26 Fluorouracil 24 Doxorubicin 24 Dexamethasone 24 Capecitabine 22 Bevacizumab 19 Prednisone 18 Vincristine 15 Oxaliplatin 15 Leucovorin 15 Etoposide 14 Drug Therapy 13 Cytarabine 13 pembrolizumab 12 Radiosurgery 12 Pemetrexed 12 Imatinib Mesylate 12 Filgrastim 12 Zoledronic Acid 11 Irinotecan 11 Surgical Procedures, Operative 10 Standard of Care 10 Goserelin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡